[HTML][HTML] Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action
S Durant, J Coulaud… - The Review of Diabetic …, 2007 - ncbi.nlm.nih.gov
The effects of bromocriptine (10 mg/kg), known to inhibit prolactin secretion and lower
autoimmune processes, were studied on glucose homeostasis in non-fasted non-obese …
autoimmune processes, were studied on glucose homeostasis in non-fasted non-obese …
A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either …
RE Scranton, JM Gaziano, D Rutty, M Ezrokhi… - BMC endocrine …, 2007 - Springer
Background Cycloset™ is a quick-release formulation of bromocriptine mesylate, a
dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts …
dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts …
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters
EM Lamos, DL Levitt, KM Munir - Primary care diabetes, 2016 - Elsevier
Dopamine action appears to play a role in changes that are seen in obesity, metabolic
syndrome and type 2 diabetes mellitus. Bromocriptine-QR (Quick Release), a dopamine …
syndrome and type 2 diabetes mellitus. Bromocriptine-QR (Quick Release), a dopamine …
Novel trajectories of bromocriptine antidiabetic action: Leptin-IL-6/JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/adiponectin, Nrf2/PARP-1, and GLP-1
E Reda, S Hassaneen, HS El-Abhar - Frontiers in Pharmacology, 2018 - frontiersin.org
Bromocriptine (BC), a sympatholytic dopaminergic D2 receptor agonist, has been
comprehensively used in clinic to treat Parkinson's disease (PD) and prolactinomas …
comprehensively used in clinic to treat Parkinson's disease (PD) and prolactinomas …
Restoration of hypothalamic signaling systems as a cause of improved metabolic parameters in rats with neonatal diabetes model during treatment with bromocriptine …
KV Derkach, AO Ivantsov, IB Sukhov… - Cell and Tissue Biology, 2017 - Springer
One approach to correction of diabetes mellitus 2 type (DM2) and its complications is the
use of bromocriptine mesylate (BCM), a selective agonist of the dopamine receptor type 2 …
use of bromocriptine mesylate (BCM), a selective agonist of the dopamine receptor type 2 …
Bromocriptine: its place in type 2 diabetes Tx
KR Sando, J Taylor - 2011 - mospace.umsystem.edu
Bromocriptine: Its place in type 2 diabetes Tx Page 1 jfponline.com Vol 60, no 11 | noVemBeR
2011 | The jouRnal of family pRacTice E1 Karen R. Sando, PharmD, CDE; James Taylor …
2011 | The jouRnal of family pRacTice E1 Karen R. Sando, PharmD, CDE; James Taylor …
Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse
Y Liang, TL Jetton, M Lubkin, AH Meier… - Cellular and Molecular …, 1998 - Springer
Dysfunction of pancreatic islets plays a crucial role in the etiology of type II diabetes. Chronic
hyperglycaemia or hyperlipidaemia may impair islet function. Previous studies by our …
hyperglycaemia or hyperlipidaemia may impair islet function. Previous studies by our …
Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes
JM Gaziano, AH Cincotta, CM O'Connor… - Diabetes …, 2010 - Am Diabetes Assoc
OBJECTIVE Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor
agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week …
agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week …
The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells.
JE De Leeuw Van Weenen, ET Parlevliet… - Biochemical …, 2010 - europepmc.org
Treatment with the dopamine receptor D2 (DRD2) agonist bromocriptine improves metabolic
features in obese patients with type 2 diabetes by a still unknown mechanism. In the present …
features in obese patients with type 2 diabetes by a still unknown mechanism. In the present …
Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial
A Ghosh, N Sengupta, P Sahana, D Giri… - Indian journal of …, 2014 - journals.lww.com
Objective: To compare the effectiveness and safety of add on therapy of bromocriptine with
metformin in type 2 diabetes mellitus (DM) patients. Material and Methods: Adult type 2 DM …
metformin in type 2 diabetes mellitus (DM) patients. Material and Methods: Adult type 2 DM …